Sort by
Refine Your Search
-
Country
-
Employer
-
Field
-
of this project is to develop anticancer molecularly targeted radiotherapy agents (theranostics) for the imaging and treatment of cancer. The focus of the project will be on specific organelle targeting with
-
contribute to ground-breaking research aimed at enhancing the effectiveness of radiotherapy treatments. Our focus lies in developing innovative approaches to sensitize tumor cells to radiotherapy, with
-
tissues in a space- and time-controlled resolution. Theranostic prodrugs detectable by nuclear magnetic resonance imaging (MRI) and able to be activated by radiotherapy clinical beams, will be developed
-
to enhance immunotherapy and radiotherapy response. Paediatric high-grade gliomas (pHGGs) are malignant, deadly tumours developing in infants and children. Mutations in histone coding genes disturb epigenetic
-
to enhance immunotherapy and radiotherapy response. Paediatric high-grade gliomas (pHGGs) are malignant, deadly tumours developing in infants and children. Mutations in histone coding genes disturb epigenetic
-
time-controlled resolution. Theranostic prodrugs detectable by nuclear magnetic resonance imaging (MRI) and able to be activated by radiotherapy clinical beams, will be developed. This project, based
-
Postdoctoral Research Associate (Genomics, Data Integration, Deep Learning, AI) - Radiation Oncology
position in Jin Zhang, PhD, MPHS’s translational genomics lab (https://sites.wustl.edu/jinzhang ) at Washington University School of Medicine, St. Louis, MO. This postdoc will also be co-advised by Michael
-
RADIOTHERAPY. Requirements Skills/Qualifications See the call Specific Requirements Candidates with a PhD (or equivalent qualification) obtained in Italy or abroad. Candidates must also be in possession of one
-
involves the synthesis of complex organic and biomolecules that will be used in targeted radiotherapy research. Some of the work involves chiral separations and an understanding of medicinal chemistry
-
are hard to treat. External beam radiotherapy and molecular radionuclide therapy in the form of 177Lu-DOTATATE have enhanced survival for some NET patients, but the long-term outlook for most patients with